To assess the metabolic alterations associated with sacubitril/valsartan therapy, particularly its effects on glycemic indices and lipid profiles in patients with cardiometabolic comorbidities.
Key Findings:
Sacubitril/valsartan therapy is associated with significant changes in metabolic indices, indicating potential clinical relevance.
Effects on glycemic control and lipid profiles were observed, including alterations in HDL, LDL, triglycerides, and total cholesterol.
Interpretation:
The findings suggest that sacubitril/valsartan may have beneficial metabolic effects, which could be relevant for patients with cardiometabolic comorbidities.
Limitations:
Variability in study designs and populations may affect the generalizability of the findings, particularly in diverse patient groups.
Potential biases in included studies, such as selection bias and reporting bias, could influence the outcomes.
Conclusion:
Sacubitril/valsartan therapy shows promise in improving metabolic parameters, warranting further investigation in diverse patient populations.
